News
XENE
39.50
-3.87%
-1.59
Baron Health Care Fund Q1 2024 Shareholder Letter
Baron Health Care Fund advanced 8.92% in the quarter ended March 31, 2024. The Fund's performance was in line with the Russell 3000 Health Care Index and the S&P 500 Index. Investments in health care equipment, pharmaceuticals, and life sciences added the most value in the period.
Seeking Alpha · 1d ago
Weekly Report: what happened at XENE last week (0415-0419)?
Weekly Report · 2d ago
Xenon Pharmaceuticals Spotlights XEN1101 Progress
TipRanks · 04/16 13:08
Xenon Pharmaceuticals Announced Two Oral Presentations For XEN1101 Clinical Data At AAN 2024 Annual Meeting
Xenon will have oral presentations at AAN. Xenon is hosting Booth #1797 in the AAN Exhibit Hall until April 17, 2024. The company will also be presenting at a session on Epilepsy Clinical Trials and Long-term Studies. XEN1101 is a Potent, Selective Potassium Channel Opener.
Benzinga · 04/16 12:41
Weekly Report: what happened at XENE last week (0408-0412)?
Weekly Report · 04/15 10:21
Xenon Pharmaceuticals Price Target Maintained With a $62.00/Share by Needham
Dow Jones · 04/12 11:13
Needham Reiterates Buy on Xenon Pharmaceuticals, Maintains $62 Price Target
Benzinga · 04/12 11:03
Buy Rating Affirmed for Xenon: A Comprehensive Analysis of Market Position and Growth Prospects
TipRanks · 04/12 10:35
Xenon Pharma to Spotlight Innovations at Investor Conference
TipRanks · 04/10 13:08
Weekly Report: what happened at XENE last week (0401-0405)?
Weekly Report · 04/08 10:25
Xenon Pharmaceuticals at Needham Healthcare Conference
TipRanks · 04/04 20:37
Xenon Pharmaceuticals is Now Oversold (XENE)
NASDAQ · 04/02 20:20
Weekly Report: what happened at XENE last week (0325-0329)?
Weekly Report · 04/01 10:24
Weekly Report: what happened at XENE last week (0318-0322)?
Weekly Report · 03/25 10:26
Weekly Report: what happened at XENE last week (0311-0315)?
Weekly Report · 03/18 10:24
Xenon Pharmaceuticals Engages at Stifel CNS Event
TipRanks · 03/12 20:38
Weekly Report: what happened at XENE last week (0304-0308)?
Weekly Report · 03/11 10:22
Xenon Pharmaceut: Current report
Press release · 03/09 00:12
Xenon Pharmaceuticals Spotlight at Biopharma Conference
TipRanks · 03/05 21:48
Buy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progress
TipRanks · 03/05 06:35
More
Webull provides a variety of real-time XENE stock news. You can receive the latest news about Xenon Pharmaceut through multiple platforms. This information may help you make smarter investment decisions.
About XENE
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).